Medical organogel processes and compositions

• US 9,205,150 B2
• Filed: 12/05/2012
• Issued: 12/08/2015
• Est. Priority Date: 12/05/2011
• Status: Active Grant

• Current Assignee: Incept LLC
• Original Assignee: Incept LLC
• Inventors: Jarrett, Peter, El-Hayek, Rami, Sawhney, Amarpreet S.
• Primary Examiner(s): Hartley, Michael G
• Assistant Examiner(s): LAMBERSKI, JENNIFER A
• Application Number:
  US13/705,808
• Publication Number:
  US 20130156752A1
• Time in Patent Office: 1,098 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/38 Albumins
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002

Abstract

Serial-solvent biomaterials are described. Embodiments include materials made in an organic solvent that are stripped of the solvent and used in a patient, where they imbibe water and form a hydrogel. These materials are useful for, among other things, delivering therapeutic agents, tissue augmentation, and radiological marking.

Claims

1. A process of making a medical material comprising crosslinking a precursor to form an organogel around a powder of a water soluble biologic, with the organogel comprising, and the precursor being crosslinked in, an organic solvent selected from anhydrous and hydrophobic solvents, methylene chloride, or dimethyl carbonate, with the water soluble biologic being directly exposed to the organic solvent and the powder being dispersed in the organogel.

2. The process of claim 1 wherein the water soluble biologic is a protein that has a molecular mass of at least about 10,000 Daltons and a sugar is associated with the protein.

3. The process of claim 1 further comprising a second powder of a second water soluble biologic, with the powder and the second powder being dispersed in the organogel.

4. The process of claim 1 wherein the organogel is formed in an absence of aqueous solution.

5. The process of claim 1 further comprising removing the organic solvent from the organogel to thereby form a xerogel.

6. The process of claim 5 wherein the organic solvent is removed by a process chosen from the group consisting of vacuum removal, lyophilization, and freezing followed by application of a vacuum.

7. The process of claim 5 wherein the xerogel is a hydrogel upon exposure to an aqueous solution.

8. The process of claim 1, wherein the organogel comprises covalently crosslinked hydrophilic polymers.

9. The process of claim 1 wherein the organogel comprises ionically crosslinked polymers.

10. The process of claim 1 wherein the organogel comprises a member chosen from the group consisting of alginate, gellan, collagen, and polysaccharide.

11. The process of claim 1, wherein the precursor is covalently crosslinked to form the organogel.

12. The process of claim 11 wherein the precursor is reacted by free radical polymerization to form the organogel.

13. The process of claim 11 wherein the precursor is a first precursor comprising a first functional group and a second precursor comprising a second functional group, with the first functional group and the second functional group being reactive in the organic solvent to form the covalent crosslinks.

14. The process of claim 13 wherein the first functional group and the second functional group are each chosen from the group consisting of electrophile and nucleophile, and the reaction between the first functional group and second functional group is an electrophilic-nucleophilic reaction that forms the covalent crosslinks.

15. The process of claim 14 wherein the electrophilic group comprises succinimide, succinimide ester, n-hydroxysuccinimide, maleimide, succinate, nitrophenyl carbonate, aldehyde, vinylsulfone, azide, hydrazide, isocyanate, diisocyanate, tosyl, tresyl, or carbonyldiimidazole.

16. The process of claim 15 wherein the nucleophile group comprises a primary amine or a primary thiol.

17. The process of claim 13 wherein the first precursor and the second precursor are water soluble.

18. The process of claim 13 wherein at least one of the first precursor and the second precursor comprises a synthetic polymer.

19. The process of claim 18 wherein the first precursor comprises a polymer chosen from the group consisting of polyethylene glycol, polyacrylic acid, polyvinylpyrrolidone, and block copolymers thereof.

20. The process of claim 1 wherein the precursor is physically crosslinked to form the organogel.

21. The process of claim 1 comprising preparing the powder of the water soluble biologic according to a method that avoids denaturation of the biologic, and, once the powder has been prepared, preventing exposure of the powder to water until the medical material is used with a patient.

22. The process of claim 1 wherein the organic solvent is an anhydrous and hydrophobic solvent.

23. The process of claim 1 wherein the organic solvent is methylene chloride.

24. The process of claim 1 wherein the organic solvent is dimethyl carbonate.

25. The process of claim 1 wherein an amount of the water soluble biologic in the powder is at least 50% w/w.

26. The process of claim 1 wherein an amount of the water soluble biologic in the powder is at least 80% w/w.

27. The process of claim 1 wherein the powder consists essentially of the water soluble biologic.

28. The process of claim 1 wherein the water soluble biologic comprises a member of the group consisting of an antibody, an antibody fragment, and a short chain variable fragment antibody.

29. The process of claim 1 wherein the water soluble biologic comprises a protein or a fusion protein.

30. The process of claim 1 wherein the water soluble biologic comprises a member of the group consisting of a carbohydrate, a polysaccharide, a nucleic acid chain, an antisense nucleic acid, a ribonucleic acid (RNA), a deoxyribonucleic acid, a small interfering RNA, and an aptamer.

31. The process of claim 1 wherein the water soluble biologic comprises an anti-vascular endothelial growth factor (VEGF) agent.

32. The process of claim 1 wherein the water soluble biologic provides for treatment of macular degeneration.

33. The process of claim 1 wherein the water soluble biologic comprises an anti-cancer agent.

34. The process of claim 1 wherein the water soluble biologic comprises insulin.

35. The process of claim 1 wherein the water soluble biologic comprises a growth factor.

36. The process of claim 1 wherein the water soluble biologic comprises a member of the group consisting of antibiotics, antineoplastic agents, hormones, angiogenic agents, anti-angiogenic agents, neurotransmitters, psychoactive drugs, chemotherapeutic drugs, drugs affecting reproductive organs, and genes.

37. The process of claim 1 wherein the water soluble biologic is for treatment of a condition selected from the group consisting of elevated intraocular pressure, fungal blepharitis, conjunctivitis, keratitis, open-angle glaucoma, ocular hypertension, inflammation of an eye, keratoconjunctivitis, and allergic conjunctivitis.

38. A process of making a medical material comprising

crosslinking a precursor to form an organogel around a powder of a water soluble biologic, with the organogel comprising, and the precursor being crosslinked in, an organic solvent selected from anhydrous and hydrophobic solvents, methylene chloride, or dimethyl carbonate, with the water soluble biologic being free of encapsulants other than the organogel and the powder being dispersed in the organogel,

making a xerogel from the organogel,

and providing the xerogel as a collection of particles, said collection being for delivery to a patient, wherein the xerogel is a hydrogel upon exposure to an aqueous solution.

39. The process of claim 38 wherein the organic solvent is an anhydrous and hydrophobic solvent.

40. The process of claim 38 wherein the organic solvent is methylene chloride.

41. The process of claim 38 wherein the organic solvent is dimethyl carbonate.

42. The process of claim 38 wherein an amount of the water soluble biologic in the powder is at least 50% w/w.

43. The process of claim 38 wherein an amount of the water soluble biologic in the powder is at least 80% w/w.

44. The process of claim 38 wherein the powder consists essentially of the water soluble biologic.

45. The process of claim 38 wherein the water soluble biologic comprises a member of the group consisting of an antibody, an antibody fragment, and a short chain variable fragment antibody.

46. The process of claim 38 wherein the water soluble biologic comprises a protein or a fusion protein.

47. The process of claim 38 wherein the water soluble biologic comprises a member of the group consisting of a carbohydrate, a polysaccharide, a nucleic acid chain, an antisense nucleic acid, a ribonucleic acid (RNA), a deoxyribonucleic acid, a small interfering RNA, and an aptamer.

48. The process of claim 38 wherein the water soluble biologic comprises an anti-vascular endothelial growth factor (VEGF) agent.

49. The process of claim 38 wherein the water soluble biologic provides for treatment of macular degeneration.

50. The process of claim 38 wherein the water soluble biologic comprises an anti-cancer agent.

51. The process of claim 38 wherein the water soluble biologic comprises insulin.

52. The process of claim 38 wherein the water soluble biologic comprises a growth factor.

53. The process of claim 38 wherein the water soluble biologic comprises a member of the group consisting of antibiotics, antineoplastic agents, hormones, angiogenic agents, anti-angiogenic agents, neurotransmitters, psychoactive drugs, chemotherapeutic drugs, drugs affecting reproductive organs, and genes.

54. The process of claim 38 wherein the water soluble biologic is for treatment of a condition selected from the group consisting of elevated intraocular pressure, fungal blepharitis, conjunctivitis, keratitis, open-angle glaucoma, ocular hypertension, inflammation of an eye, keratoconjunctivitis, and allergic conjunctivitis.